Public Equity

Investing in Innovation
since 2003

Passionate & disciplined commitment to supporting biopharma companies

The strategy centers on an unwavering commitment to deep value and fundamentally-driven investing. We leverage extensive proprietary research into medical, scientific and financial considerations to identify misunderstood drug development companies that therefore create compelling opportunities for significant returns.

By the Numbers

Over 225

Completed Directly Negotiated Investments


years of collective investing experience

$500M - $1.5B

Median Market Cap
Investor Login